| Introduction | For Patients | For Science | For Society | Looking Ahead Hereditary angioedema (HAE) is a rare genetic disease that causes recurrent episodes of severe swelling in different parts of the body. These attacks are unpredictable, vary in severity and affect areas including the abdomen, face, extremities and throat. Swelling in the throat can become lifethreatening if it blocks the airway. Although HAE affects only around 1 in 50,000 people worldwide, the impact on those living with the condition can be profound. Most HAE patients (76%) said the condition disrupted their lives and limited productivity, according to four multinational surveys CSL Behring conducted across Europe (n = 479). Forty to 70% said they skipped leisure activities due to fear, anxiety or risk of attacks.* The experience of HAE differs from person to person and can change over time. Treatment needs may vary depending on an individual’s disease burden, goals, life stage and personal preferences. This reinforces the importance of access to treatment options that support more individualised care. Building on its longstanding commitment to the HAE community, CSL continues to expand treatment options for people living with the condition. Our aim is to support patients across the continuum of care, helping to both prevent and treat acute episodes. Supporting People Across the Hereditary Angioedema Care Journey HAE is one of the most difficult things I’ve faced. But with modern long-term prophylaxis, I often forget I have this unpredictable rare disease. I’m grateful that I can enjoy my retirement, travel around the world, spend time with my grandkids and embrace other activities I love that make life exciting... Julie, lives with hereditary angioedema *Source: Metcalfe, A et al., 2025. Poster Presentation, Global Angioedema Leadership Conference (GALC) 2025, Madrid, Spain. 14 | CSL IMPACT REPORT 2026
RkJQdWJsaXNoZXIy MjE2NDg3